BGNE241220P280000
- 0.00
- 0.000.00%
BeiGene Newsroom
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
Top Gap Ups and Downs on Wednesday: SONY, DELL, ADSK and More
Why Is BeiGene Stock Trading Higher On Wednesday?
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
European Commission Approves Products by BeiGene, GSK and Novartis
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval
Express News | The European Commission Has Approved BeiGene's Tevimbra (Tislelizumab) In Combination With Chemotherapy For The First-line Treatment Of Esophageal Squamous Cell Carcinoma And Gastric Or Gastroesophageal Junction Adenocarcinoma
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
Express News | European Commission Approves Beigene’s Tevimbra for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Beigene issued approximately 0.5 million shares due to the exercise of stock options.
Beigene (06160) announced that the company will issue approximately 0.5 million shares on November 26, 2024, due to a director exercising stock options.
Beigene (06160.HK) exercised the right to purchase shares and issued 0.5 million shares.
Beigene (06160.HK) announced on November 27 that approximately 0.5 million ordinary shares were issued due to a director exercising stock options on November 26, 2024.
BeiGene to Present at Upcoming Investor Conferences
Express News | Beigene Ltd : JP Morgan Cuts Target Price to $234 From $235
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
Research reports mining丨 china merchants: Initiating coverage on beigene with a "strongly recommended" rating, bullish on the rapid expansion of products like zebutini in the short to medium term.
China Merchants Securities research reports point out that Beigene (688235.SH) is an international pharmaceutical company that has completed the global sales of innovative products. Its profound understanding of disease areas and scientific layout are fundamental to ensuring sustained competitiveness. Beigene's rapid growth in sales of products like Zebutini in the short to medium term is viewed as bullish, as is the competitiveness of its pipeline products in the medium to long term. The firm expects Beigene's revenue for 2024-2026 to be 26.87 billion yuan, 33.82 billion yuan, and 42.46 billion yuan respectively, with year-on-year growth of 54%, 26%, and 26%. Significant reduction in losses is anticipated in 2024, with profits for 2024-2026 projected to be a loss of 4.
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Hong Kong stocks unusual movement | Beigene (06160) rose nearly 3% intraday as PRMT5 inhibitors approved for clinical use in China, expecting intensive catalysis next year.
Beigene (06160) rose nearly 3% during the session, as of the time of writing, it rose by 2.29%, closing at 120.5 Hong Kong dollars, with a turnover of 0.14 billion Hong Kong dollars.
China ADRs Have Increased to the Largest Share Since Late 2021 – GS